Racial Differences in Systemic Immune Parameters in Individuals With Lung Cancer

Mitchell S. von Itzstein, MD; Jialiang Liu, PhD; Hong Mu-Mosley, PhD; Farjana Fattah, PhD; Jason Y. Park, MD, PhD; Jeffrey A. SoRelle, MD; J. David Farrar, PhD; Mary E. Gwin, MD; David Hsiehchen, MD; Yvonne Gloria-McCutchen; Edward K. Wakeland, PhD; Suzanne Cole, MD; Sheena Bhalla, MD; Radhika Kainthla, MD; Igor Puzanov, MD, MSCI; Benjamin Switzer, DO, MHSA, MS; Gregory A. Daniels, MD, PhD; Yousef Zakharia, MD; Montaser Shaheen, MD; Jianjun Zhang, MD, PhD; Yang Xie, PhD; David E. Gerber, MD

JTO Clinical and Research Reports (Jan 2025)

Racial Differences in Systemic Immune Parameters in Individuals With Lung Cancer

Mitchell S. von Itzstein, MD,
Jialiang Liu, PhD,
Hong Mu-Mosley, PhD,
Farjana Fattah, PhD,
Jason Y. Park, MD, PhD,
Jeffrey A. SoRelle, MD,
J. David Farrar, PhD,
Mary E. Gwin, MD,
David Hsiehchen, MD,
Yvonne Gloria-McCutchen,
Edward K. Wakeland, PhD,
Suzanne Cole, MD,
Sheena Bhalla, MD,
Radhika Kainthla, MD,
Igor Puzanov, MD, MSCI,
Benjamin Switzer, DO, MHSA, MS,
Gregory A. Daniels, MD, PhD,
Yousef Zakharia, MD,
Montaser Shaheen, MD,
Jianjun Zhang, MD, PhD,
Yang Xie, PhD,
David E. Gerber, MD

Affiliations

Mitchell S. von Itzstein, MD: Department of Internal Medicine (Division of Hematology-Oncology), University of Texas Southwestern Medical Center, Dallas, Texas; Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas
Jialiang Liu, PhD: Quantitative Biomedical Research Center, University of Texas Southwestern Medical Center, Dallas, Texas
Hong Mu-Mosley, PhD: Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas
Farjana Fattah, PhD: Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas
Jason Y. Park, MD, PhD: Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas
Jeffrey A. SoRelle, MD: Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas
J. David Farrar, PhD: Department of Immunology, University of Texas Southwestern Medical Center. Dallas, Texas
Mary E. Gwin, MD: Department of Internal Medicine (Division of Hematology-Oncology), University of Texas Southwestern Medical Center, Dallas, Texas; Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas
David Hsiehchen, MD: Department of Internal Medicine (Division of Hematology-Oncology), University of Texas Southwestern Medical Center, Dallas, Texas; Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas
Yvonne Gloria-McCutchen: Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas
Edward K. Wakeland, PhD: Department of Immunology, University of Texas Southwestern Medical Center. Dallas, Texas
Suzanne Cole, MD: Department of Internal Medicine (Division of Hematology-Oncology), University of Texas Southwestern Medical Center, Dallas, Texas; Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas
Sheena Bhalla, MD: Department of Internal Medicine (Division of Hematology-Oncology), University of Texas Southwestern Medical Center, Dallas, Texas; Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas
Radhika Kainthla, MD: Department of Internal Medicine (Division of Hematology-Oncology), University of Texas Southwestern Medical Center, Dallas, Texas; Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas
Igor Puzanov, MD, MSCI: Roswell Park Comprehensive Cancer Center, Buffalo, New York
Benjamin Switzer, DO, MHSA, MS: Roswell Park Comprehensive Cancer Center, Buffalo, New York
Gregory A. Daniels, MD, PhD: Moores Cancer Center, University of California San Diego Health, San Diego, California
Yousef Zakharia, MD: University of Iowa Hospitals and Clinics, Iowa City, Iowa
Montaser Shaheen, MD: University of Texas Health Science Center, San Antonio, Texas
Jianjun Zhang, MD, PhD: MD Anderson Cancer Center, Houston, Texas
Yang Xie, PhD: Quantitative Biomedical Research Center, University of Texas Southwestern Medical Center, Dallas, Texas; Peter O’Donnell Jr. School of Public Health, University of Texas Southwestern Medical Center, Dallas, Texas
David E. Gerber, MD: Department of Internal Medicine (Division of Hematology-Oncology), University of Texas Southwestern Medical Center, Dallas, Texas; Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas; Peter O’Donnell Jr. School of Public Health, University of Texas Southwestern Medical Center, Dallas, Texas; Corresponding author. Address for correspondence: David E. Gerber, MD, Division of Hematology-Oncology, Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Mail Code 8852, Dallas, Texas 75390-8852.

Journal volume & issue: Vol. 6, no. 1
p. 100751

Abstract

Read online

Introduction: Racial and ethnic disparities in the presentation and outcomes of lung cancer are widely known. To evaluate potential factors contributing to these observations, we measured systemic immune parameters in Black and White patients with lung cancer. Methods: Patients scheduled to receive cancer immunotherapy were enrolled in a multi-institutional prospective biospecimen collection registry. Clinical and demographic information were obtained from electronic medical records. Pretreatment peripheral blood samples were collected and analyzed for cytokines using a multiplex panel and for immune cell populations using mass cytometry. Differences between Black and White patients were determined and corrected for multiple comparisons. Results: A total of 187 patients with NSCLC (Black, 19; White, 168) were included in the analysis. Compared with White patients, Black patients had greater comorbidity (median Charlson Comorbidity Index 5 versus 3; p = 0.04) and were more likely to have received previous chemotherapy (79% versus 47%; p = 0.03). Black patients had significantly lower levels of CCL23 and CCL27 and significantly higher levels of CCL8, CXCL1, CCL26, CCL25, CCL1, IL-1b, CXCL16, and IFN-γ (all p < 0.05, false discovery rate < 0.1). Black patients also exhibited greater populations of nonclassical CD16+ monocytes, NKT-like cells, CD4+ cells, CD38+ monocytes, and CD57+ gamma delta T cells (all p < 0.05). Conclusions: Black and White patients with lung cancer exhibit several differences in immune parameters, with Black patients exhibiting greater levels of numerous proinflammatory cytokines and cell populations. The etiology and clinical significance of these differences warrant further evaluation.

Published in JTO Clinical and Research Reports

ISSN: 2666-3643 (Online)
Publisher: Elsevier
Country of publisher: United States
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://www.journals.elsevier.com/jto-clinical-and-research-reports/

About the journal

Abstract

Keywords